Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. 1993

M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
Division of Hematology, University of Michigan, Ann Arbor.

BACKGROUND Many patients with non-Hodgkin's lymphomas are not cured by current therapies, and new approaches to treatment are needed. As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with 131I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed. RESULTS Anti-B1 (anti-CD20) mouse monoclonal antibody trace-labeled with 131I (15 mg containing 5 mCi) was given intravenously at approximately one-week intervals: first, without pretreatment with unlabeled anti-B1 antibody, to all 10 patients; then, with pretreatment with 135 mg of unlabeled antibody, to 8 patients; and then, with pretreatment with 685 mg, to 2 patients. Serial quantitative gamma-camera images and measures of whole-body radioactivity were obtained after each tracer dose. All known disease sites larger than 2 cm could be imaged. The effect of a pretreatment dose of unlabeled anti-B1 antibody on targeting of the tumor with the radiolabeled antibody was variable. The pretreatment dose of unlabeled antibody that produced the highest ratio of the tumor dose to the whole-body dose in tracer studies was then used to deliver higher doses of radioactivity for radioimmunotherapy in nine patients. Three patients received doses designed to deliver 25 cGy to the whole body (two patients treated twice, six to eight weeks apart), four patients received 35 cGy (one patient treated twice), and two patients received 45 cGy (one patient treated twice); each dose contained 34 to 66 mCi of activity. Six of the nine treated patients had tumor responses, including patients with bulky or chemotherapy-resistant disease: four patients had complete remissions, and two had partial responses. Three patients had objective responses to tracer infusions before they received radioimmunotherapeutic doses. Of the four patients with complete remissions, one remained in remission for eight months and the other three continue to have no disease progression (for 11, 9, and 8 months). There was mild or no myelosuppression. CONCLUSIONS Radioimmunotherapy with [131I]anti-B1 antibody is a promising new treatment for lymphoma.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011829 Radiation Dosage The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv). Sievert Units,Dosage, Radiation,Gray Units,Gy Radiation,Sv Radiation Dose Equivalent,Dosages, Radiation,Radiation Dosages,Units, Gray,Units, Sievert
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000944 Antigens, Differentiation, B-Lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin. Antigens, Differentiation, B-Cell,B-Cell Differentiation Antigens,B-Lymphocyte Differentiation Antigens,Blast-2 Antigen, B-Cell,Differentiation Antigens, B-Cell,Differentiation Antigens, B-Lymphocyte,Leu Antigens, B-Lymphocyte,Plasma Cell Antigens PC-1,Antigens, Differentiation, B Lymphocyte,Antigens, Plasma Cell, PC-1,B-Cell Blast-2 Antigen,Antigen, B-Cell Blast-2,Antigens, B-Cell Differentiation,Antigens, B-Lymphocyte Differentiation,Antigens, B-Lymphocyte Leu,B Cell Blast 2 Antigen,B Cell Differentiation Antigens,B Lymphocyte Differentiation Antigens,B-Lymphocyte Leu Antigens,Blast 2 Antigen, B Cell,Differentiation Antigens, B Cell,Differentiation Antigens, B Lymphocyte,Leu Antigens, B Lymphocyte,Plasma Cell Antigens PC 1

Related Publications

M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
March 2006, Clinical and experimental medicine,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
March 2009, Nihon Hoshasen Gijutsu Gakkai zasshi,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
August 1995, Lancet (London, England),
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
March 2002, Journal of the American Academy of Dermatology,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
December 1986, Cancer research,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
January 2002, Nihon rinsho. Japanese journal of clinical medicine,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
April 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
January 2009, Nuklearmedizin. Nuclear medicine,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
May 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
M S Kaminski, and K R Zasadny, and I R Francis, and A W Milik, and C W Ross, and S D Moon, and S M Crawford, and J M Burgess, and N A Petry, and G M Butchko
October 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!